Hims & Hers, the leading health and wellness platform, today announced a first-of-its-kind* intelligent care experience that puts AI directly inside customers’ care, not on the sidelines of it. Rolling out first to Hers weight loss members, this proactive care experience delivers personalized guida…
Hims & Hers Health Inc. (NYSE:HIMS) shares are trading higher on Friday as traders continue to weigh fresh regulatory scrutiny against a generally risk-on tape. Here’s what investors need to know.What Is Driving Hims & Hers Health’s Stock Today?The FTC is reportedly preparing a lawsuit alleging Him…
LOS ANGELES, July 31, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Hims & Hers Health, Inc. (" Hims & Hers" or "the Company") (NYSE: HIMS) for violations of the securitie…
Shares of Hims & Hers Health, Inc. (HIMS) are headed for a fourth consecutive weekly loss as a fresh Federal Trade Commission (FTC) lawsuit adds to legal risk and Morningstar sticks with its ‘No Moat’ view and ‘Very High’ uncertainty rating.HIMS stock jumped 8% on Thursday but remained on track for…
Explore more price target data and ratings for Hims & Hers Health, Inc. on the Forecasts tab, and track all previous and future analyst recommendations for Hims & Hers Health, Inc. in the dedicated News Flow.Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. T…
Hims & Hers (HIMS) shares slumped 13% on Wednesday after the U.S. Federal Trade Commission sued the telehealth company over allegations it shared sensitive user health data with advertisers, including Meta Platforms and Snap, while also engaging in deceptive billing and cancellation practices.FTC’s…
Shares of Hims & Hers Health, Inc. (HIMS) are attempting a rebound after three straight weeks of losses, with BlackRock’s latest stake disclosure and renewed peptide optimism giving bulls fresh reasons to watch the stock into its second-quarter (Q2) earnings.HIMS stock is up about 4% so far this we…
Shares of Hims & Hers Health, Inc. (HIMS) rose 1% overnight late Sunday as retail dip-buying interest picked up after Friday’s selloff and a mixed Food and Drug Administration (FDA) panel decision on seven popular peptides.HIMS stock plunged 14% on Friday, marking its worst session in nearly six mo…
What Happened? A number of stocks fell in the morning session after concerns grew over a rising number of uninsured patients. The trend was highlighted in HCA Healthcare's recent earnings report, which pointed to a 'negative payer mix shift.' This term refers to a change in the types of insurance p…
Shares of Hims & Hers Health, Inc. (HIMS) climbed 1% in overnight trading late Thursday after a divided Food and Drug Administration (FDA) advisory panel recommended easing restrictions on four popular peptides, potentially opening a sizable new market for telehealth firms.HIMS stock jumped more th…
Shares of Hims & Hers Health, Inc. (HIMS) extended their decline to a third consecutive session on Monday as a newly disclosed stock sale by CFO Oluyemi Okupe drew attention ahead of a closely-watched FDA meeting on compounded peptides.HIMS stock fell 0.4% on Monday to finish at $32.7, wish shares…
Hims & Hers Health (NYSE:HIMS) will report Q2 2026 results and host a 5:00 p.m. ET earnings call Aug. 10 as it positions to capture up to 20% of a $2.2B telehealth peptide market with in‑house manufacturing, even as Chief Accounting Officer Irene Becklund plans to depart Oct. 9.Previous Week Recap…
